A Phase Ib Open-Label Study of the Safety Tolerability Pharmacokinetics and Activity of Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients with HER2-Positive Metastatic Breast Cancer Who Have Progressed On Prev
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to test the safety of different doses of GDC-0941 when given with trastuzumab-MCC-DM1 and when GDC 0941 is given with trastuzumab.
Description
The purpose of this study is to test the safety of different doses of GDC-0941 when given with trastuzumab-MCC-DM1 and when GDC 0941 is given with trastuzumab.
Details
| Condition | Breast Cancer |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX1636 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.